Effect of preoperative oral pravastatin reload in systemic inflammatory response and myocardial damage after coronary artery bypass grafting: A pilot double-blind placebo-controlled study

Journal of Cardiovascular Surgery

Volumn 56, Issue 4, 2015, Pages 617-629

  Castano M ^a   Gonzalez Santos J M ^b   Lopez J ^b   Garcia B ^c   Centeno, J E ^b   Aparicio, B ^b   Bueno, M J ^b   Diez R ^b   Sagredo, V ^b   Rodriguez J M ^b   Garcia Criado F J ^c  

^a UNIVERSITY OF LEÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cardiopulmonary bypass; Inflammation; Nitric oxide

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CD18 ANTIGEN; CREATINE KINASE MB; CREATININE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; L SELECTIN; NITRIC OXIDE SYNTHASE; PLACEBO; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NOS2 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; ENZYME RELEASE; FOLLOW UP; HEART MUSCLE INJURY; HUMAN; INTRAOPERATIVE PERIOD; LONG TERM CARE; MIDDLE AGED; NITRATE METABOLISM; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ADVERSE EFFECTS; AGED; BLOOD; CARDIOPULMONARY BYPASS; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; DYSLIPIDEMIAS; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PILOT STUDY; PREOPERATIVE CARE; RISK FACTOR; SPAIN; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CREATINE KINASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PILOT PROJECTS; PRAVASTATIN; PREOPERATIVE CARE; RISK FACTORS; SPAIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938876062     PISSN: 00219509     EISSN: 1827191X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wolfram S, Grimm M, Heidbreder M, Dendorfer A, Katus HA, Liao JK et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003;41:474-80.
2. Lefer AM. Nitric oxide: Nature's naturally occurring leukocyte inhibitor. Circulation 1997;95:553-4.
3. Morales-Villegas EC, Di Sciascio G, Briguori C. Statins: cardiovascular risk reduction in percutaneous coronary interventionbasic and clinical evidence of hyperacute use of statins. Int J Hypertens 2011;2011:904742.
4. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
5. Liakopoulos OJ, Dorge H, Schmitto JD, Nagorsnik U, Grabedunkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg 2006;54:250-4.
6. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;132:392-400.
7. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial. J Thorac Cardiovasc Surg 2008;136:1541-8.
8. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the armyda-3 (atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006;114:1455-61.
9. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the armyda-acs randomized trial. J Am Coll Cardiol 2007;49:1272-8.
10. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A et al. Novel approaches for preventing or limiting events (naples) ii trial: Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63.
11. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the armyda-recapture (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol 2009;54:558-65.
12. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005;45:1287-91.
13. Berkan O, Katrancioglu N, Ozker E, Ozerdem G, Bakici Z, Yilmaz MB. Reduced p-selectin in hearts pretreated with fluvastatin: A novel benefit for patients undergoing open heart surgery. Thorac Cardiovasc Surg 2009;57:91-5.
14. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30, 000 patients. Eur Heart J 2008;29:1548-9.
15. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: Taking a risk for cardioprotection. Heart Fail Rev 2007;12:217-34.
16. Ludman AJ, Hausenloy DJ, Babu G, Hasleton J, Venugopal V, Boston-Griffiths E et al. Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: A randomised controlled trial. Basic Res Cardiol 2011;106:1387-95.
17. Bourbon A, Vionnet M, Leprince P, Vaissier E, Copeland J, McDonagh P et al. The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. Eur J Cardiothorac Surg 2004;26:932-8.
18. Youn YN, Park SY, Hwang Y, Joo HC, Yoo KJ. Impact of highdose statin pretreatment in patients with stable angina during off-pump coronary artery bypass. Korean J Thorac Cardiovasc Surg 2011;44:208-14.
19. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of c3a and c5a anaphylatoxins. N Engl J Med 1981;304:497-503.
20. Hayashi Y, Sawa Y, Fukuyama N, Nakazawa H, Matsuda H. Inducible nitric oxide production is an adaptation to cardiopulmonary bypass-induced inflammatory response. Ann Thorac Surg 2001;72:149-55.
21. Tamayo E, Alvarez FJ, Alonso O, Bustamante R, Castrodeza J, Soria S et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2009;50:687-94.
22. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-7.
23. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates il-6 and c-reactive protein, but not il-1 and tnf-alpha, in cardiopulmonary bypass. Eur Cytokine Netw 2008;19:99-103.
24. Krivoy N, Adler Z, Saloma R, Hawadie A, Azzam ZS. Targeting c-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol 2008;13:171-4.
25. Kawahito K, Kobayashi E, Ohmori M, Harada K, Kitoh Y, Fujimura A et al. Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: Increased aggregability and superoxide producing capacity. Artif Organs 2000;24:37-42.
26. Clermont G, Vergely C, Jazayeri S, Lahet JJ, Goudeau JJ, Lecour S et al. Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology 2002;96:80-7.
27. Mangano DT. Biventricular function after myocardial revascularization in humans: deterioration and recovery patterns during the first 24 hours. Anesthesiology 1985;62:571-7.
28. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and mhc class i antigen processing. Immunol Rev 2005;207:19-30.
29. Ma XL, Tsao PS, Lefer AM. Antibody to cd-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88:1237-43.
30. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997;85:766-82.
31. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. II-10 inhibits metalloproteinase and stimulates timp-1 production in human mononuclear phagocytes. J Clin Invest 1995;96:2304-10.
32. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clin Chem 2005;51:1735-8.
33. Wu SY, Fang HY. [effects of pravastatin on myocardial connexin 43, ifn-gamma and il-10 expressions in a murine model of viral myocarditis induced by coxsackievirus b3]. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:72-6.
34. Sun YM, Tian Y, Li X, Liu YY, Wang LF, Li J et al. Effect of atorvastatin on expression of il-10 and tnf-alpha mrna in myocardial ischemia-reperfusion injury in rats. Biochem Biophys Res Commun 2009;382:336-340
35. Ruvolo G, Speziale G, Greco E, Tritapepe L, Mollace V, Nistico G et al. Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 1995;9:651-4.
36. Schulze C, Conrad N, Schutz A, Egi K, Reichenspurner H, Reichart B et al. Reduced expression of systemic proinflammatory cytokines after off-pump versus conventional coronary artery bypass grafting. Thorac Cardiovasc Surg 2000;48:364-9.
37. Hayashi Y, Sawa Y, Nishimura M, Fukuyama N, Ichikawa H, Ohtake S et al. Peroxynitrite, a product between nitric oxide and superoxide anion, plays a cytotoxic role in the development of post-bypass systemic inflammatory response. Eur J Cardiothorac Surg 2004;26:276-80.
38. Sasmazel A, Baysal A, Fedekar A, Buyukbayrak F, Bugra O, Erdem H et al. The effect of statin therapy on stimulation of endothelium-derived nitric oxide before and after coronary artery bypass surgery. Heart Surg Forum 2010;13:E243-6.
39. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;32:136-40.
40. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41.
41. Tomaszewski M, Stepien KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep 2011;63:859-66.